Skip to content
MarketScale
Demo
‹ Back to IndustriesSciences

Almost 25% of Prescribed Antibiotics Are Unnecessary, Says Study

A study published in the medical journal The BMJ showed that 23 percent of prescriptions from 2016 in the United States were unnecessary.   The most common conditions that were prescribed such antibiotics included acute bronchitis, upper respiratory infections and coughing. These conditions are caused by viruses — not bacteria — which means that antibiotics are useless…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · MedicinePrescriptions
Share

Key takeaways

01

A study published in the medical journal The BMJ showed that 23 percent of prescriptions from 2016 in the United States were unnecessary.

02

The most common conditions that were prescribed such antibiotics included acute bronchitis, upper respiratory infections and coughing.

03

These conditions are caused by viruses — not bacteria — which means that antibiotics are useless…

Get featured

Want to get featured in MarketScale Sciences?

Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.

Request an invite

A study published in the medical journal The BMJ showed that 23 percent of prescriptions from 2016 in the United States were unnecessary.

The most common conditions that were prescribed such antibiotics included acute bronchitis, upper respiratory infections and coughing. These conditions are caused by viruses — not bacteria — which means that antibiotics are useless in treating them.

For the latest news, videos, and podcasts in the Science Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – twitter.com/ScienceMKSL

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences

Follow Sciences Insights

Get new expert content in your inbox.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free plan

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Sciences Insights

ENEOS ran an AI controller on a distillation column for 35 days and cut steam use 40%

ENEOS ran an AI controller on a distillation column for 35 days and cut steam use 40%

ENEOS Materials and Yokogawa ran an autonomous AI controller on a butadiene distillation column for 35 days and cut steam use 40%. It’s a real operations proof point. It also puts integration and governance gaps front and center.

  • 01A 35-day closed-loop run is a stronger autonomy proof point than a demo, it forces plants to prove handover, fallback, and KPIs over real feed and operating swings.
  • 02Steam reduction claims are compelling, but procurement and ops teams should pin vendors to baselines, operating envelopes, and how off-spec avoidance is measured.
  • 03Agentic AI is showing up as “work management” and “shift checklist” agents before it replaces control engineers, which shifts requirements toward clean, permissioned data access.

Sep 13, 2026

Novaspace sees 6,500+ Earth observation satellites by 2035, and value shifts to payload integration

Novaspace sees 6,500+ Earth observation satellites by 2035, and value shifts to payload integration

Novaspace forecasts more than 6,500 Earth observation satellites launching by 2035. It also projects $155.9 billion in manufacturing revenue, based on a SpaceNews-posted release dated Aug. 21, 2026. As defense-led demand shifts toward revisit rate and persistence, payload integration and fleet interoperability become the hard parts.

  • 01$155.9 billion is tied specifically to satellite manufacturing, not launch or ground, which should reshape how teams size supplier commitments and make-buy decisions.
  • 02Novaspace’s “skyscraper model” framing implies procurement power is shifting to payload integration, test capacity, and software-defined operations, even as the bus becomes more standardized.

Sep 13, 2026

Samsung Biologics reports $262M manufacturing deal running through 2033

Samsung Biologics reports $262M manufacturing deal running through 2033

Samsung Biologics disclosed a $262 million biologics manufacturing contract running through 2033. The work will be produced at Songdo, South Korea. The deal lifts Samsung Biologics’ cumulative contract value above $21.9 billion, per BioPharm International.

  • 01Duration is the headline: Samsung Biologics’ new $262 million contract with an unnamed European pharma company runs through Dec. 31, 2033, a long-dated commitment for the Songdo site (per BioPharm International).
  • 02CDMO selection is drifting toward “operating model”: Samsung Biologics’ Kasper Øland said clients more often want a CDMO that operates like part of their own operations, with more predictability, transparency, and timeline flexibility (per BioPharm International).

Sep 13, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For Sciences teams

See how Sciences teams use MarketScale →

Executive Thought Leadership

Explore Channels

Industry news, analysis, and expert perspectives

Professional AV›Engineering & Construction›Education Technology›Healthcare›Energy›Software & Technology›Retail›Business Services›Industrial IoT›Sports & Entertainment›Transportation›Sciences›Building Management›Food & Beverage›Architecture & Design›Hospitality›Marketing Tech›
Keep exploring

More from Sciences

Sciences hubMore expert Sciences coverage.Explore →Executive Thought LeadershipPut researchers on the record.Explore →FinThriveComplex topics, made clear.Explore →State of GEO & AI VisibilityHow B2B brands get cited by AI search.Explore →

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512